Petros pharmaceuticals announces deconsolidation of metuchen pharmaceuticals subsidiary, strengthening its balance sheet and improving the company's equity position

New york, ny / access newswire / june 25, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, metuchen pharmaceuticals llc ("metuchen"), including its wholly owned subsidiaries, timm medical technologies, inc. and pos-t-vac, llc, from its consolidated balance sheet, effective beginning in its quarterly report on form 10-q for the quarter ending june 30, 2025. this move is expected to significantly improve petros' financial position, increasing stockholders' equity and materially reducing consolidated debt.
PTPI Ratings Summary
PTPI Quant Ranking